AU researchers have discovered several drug resistance genes that can be potentially used as therapeutic targets for cancer treatment. We also describe synergistic combinations between these genes and a large number of anticancer drugs that have been approved by the FDA for clinical use or clinical trials. Therefore, these genes alone or in combination with existing drugs can offer more efficient treatment for cancer.